{
  "item1": "2016, entered into collaboration Moderna identification development mRNA therapeutics encoding CFTR treatment CF. December 2022, FDA cleared Investigational New Drug Application (“IND”) VX-522, mRNA therapeutic developing Moderna pursuant collaboration. multiple ascending dose portion Phase 1/2 clinical trial VX-522 people CF ongoing. expect share data clinical trial first half 2025.",
  "item7": "ITEM 7. MANAGEMENT’S DISCUSSION ANALYSIS FINANCIAL CONDITION RESULTS OPERATIONS OVERVIEW global biotechnology company invests scientific innovation create transformative people serious diseases, focus specialty markets. seven approved medicines: five treat underlying cause cystic fibrosis (“CF”), life-threatening genetic disease, one treats severe sickle cell disease (“SCD”) transfusion dependent beta thalassemia (“TDT”), life shortening inherited blood disorders, one treats moderate-to-severe acute pain. clinical-stage pipeline includes programs CF, SCD, beta thalassemia, acute peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy other autoimmune renal diseases cytopenias, type 1 diabetes, myotonic dystrophy type 1, autosomal dominant polycystic kidney disease.",
  "item2": "Item 2. Management’s Discussion Analysis Financial Condition Results Operations OVERVIEW global biotechnology company invests scientific innovation create transformative medicines people serious diseases, focus specialty markets. seven approved medicines: five treat underlying cause cystic fibrosis (“CF”), life-threatening genetic disease, one treats severe sickle cell disease (“SCD”) transfusion dependent beta thalassemia (“TDT”), life shortening inherited blood disorders, one treats moderate-to-severe acute pain. clinical-stage pipeline includes programs CF, SCD, beta thalassemia, neuropathic pain, type 1 diabetes, IgA nephropathy, primary membranous nephropathy other autoimmune renal diseases cytopenias, APOL1-mediated kidney disease, autosomal dominant polycystic kidney disease myotonic dystrophy type 1."
}